Fusion Pharmaceuticals Inc logo

FUSN - Fusion Pharmaceuticals Inc News Story

$8.51 0.3  3.7%

Last Trade - 29/07/21

Small Cap
Market Cap £250.8m
Enterprise Value £87.3m
Revenue £n/a
Position in Universe 4090th / 7008

Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Tue 11th May, 2021 4:21pm
* Fusion Pharmaceuticals Inc  FUSN.OQ  reported a quarterly
adjusted loss of 42 cents​​ per share for the quarter ended
in March. The mean expectation of three analysts for the quarter
was for a loss of 29 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Fusion Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 42 cents​.
* The mean earnings estimate of analysts had fallen by
about 4.8% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Fusion Pharmaceuticals Inc shares had fallen by 17.9% this
quarter and lost 25.1% so far this year.
* The company reported a quarterly loss of $17.53 million.
* Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $23.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 11 at 03:21 p.m. GMT.
​All figures in US dollars
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.